The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients.
Studies have reported a beneficial role of trastuzumab combined to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma. However, the effect of taxanes combined with platin-5FU + trastuzumab (TPFT) is understudied. In this context, the aim of this study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients.
Study Type
OBSERVATIONAL
Enrollment
65
docetaxel or paclitaxel
CHU Besancon
Besançon, Franche-Comté, France
Progression free survival
PFS will be defined as the time interval between the date of randomization and the date of first progression (local, regional, metastatic, second cancer) or death regardless of the cause. Patients alive without progression will be censored at the time of the latest news
Time frame: up to 12 years
Overall survival
OS will be calculated between the date of randomization and the date of death from any cause. . Alive patients or lost to follow-up at the time of the analysis will be censored at the date of last follow-up.
Time frame: up to 12 years
Objective Response Rate
Evaluated by RECIST criteria version 1.1
Time frame: up to 12 years
disease control rate
Time frame: up to 12 years
secondary resectability of primary tumor or metastases in patients with DCR
Time frame: up to 12 years
Tolerance
graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] criteria v4.03
Time frame: up to 12 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.